Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Broad based buying in markets
Thu, 13 Mar 11:30 am

After opening firm, the Indian indices are trading well above the dotted line in the morning session. Apart from software and pharma stocks, all sectoral indices are trading in the green. The buying interest is highest auto and banking stocks.

The BSE-Sensex is trading up 90 points and the NSE-Nifty is trading up 30 points. The BSE Mid Cap index is trading up 0.6% and the BSE Small Cap index is trading up 0.5%. The rupee is trading at 60.95 to the US dollar.

Software stocks are trading mixed today. While Tata Consultancy Services (TCS) is leading the gainers, Infosys is leading the losses. India's second largest software firm, Infosys, might need a longer time to get back to an Industry level growth rate, according to Chairman N.R. Narayana Murthy. At an investor conference, he has expressed his displeasure at the problems that the company is facing. As per him, Infosys has not been able to take any advantage of the depreciation of the rupee and that operating margins will remain under pressure in the near term. He expects growth to pick up only towards the end of FY15. He also indicated that the exodus of management talent from the company may not be over by saying that many more resignations could be expected. Infosys is trading down 7% today.

Indian Pharma stocks are trading on a mixed note today. While Sun Pharma is leading the losers, Orchid Chemicals and Panacea Biotech are trading firm today. As per a leading business daily, Sun Pharma has received an import alert from USFDA (United States Food and Drug Administration) for all products manufactured at its Karkhadi plant in Gujarat. It received an import alert and effectively a ban for all its API (active pharmaceutical ingredients) and formulations that it manufactures at its Gujarat plant. It may be noted that the move comes when its subsidiary, Caraco recently received USFDA approval for marketing of the company's Risperidone, a mental disorder drug. Also that the company has recently recalled over 2,500 drug bottles from US markets after it received customer's complaints. The company's financial impact on the ban of Gujarat plant is yet to be known. The ban is the result of the detention without physical examination of drugs which have not met the good manufacturing practices, according to the USFDA norms. Further, Ranbaxy and Wockhardt are already under the USFDA scanner for numerous import alerts.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Broad based buying in markets". Click here!

  

Related Views on News

INFOSYS Announces Quarterly Results (3QFY21); Net Profit Up 16.8% (Quarterly Result Update)

Jan 14, 2021 | Updated on Jan 14, 2021

For the quarter ended December 2020, INFOSYS has posted a net profit of Rs 52 bn (up 16.8% YoY). Sales on the other hand came in at Rs 259 bn (up 12.3% YoY). Read on for a complete analysis of INFOSYS's quarterly results.

INFOSYS Announces Quarterly Results (2QFY21); Net Profit Up 20.3% (Quarterly Result Update)

Oct 15, 2020 | Updated on Oct 15, 2020

For the quarter ended September 2020, INFOSYS has posted a net profit of Rs 49 bn (up 20.3% YoY). Sales on the other hand came in at Rs 246 bn (up 8.6% YoY). Read on for a complete analysis of INFOSYS's quarterly results.

INFOSYS 2019-20 Annual Report Analysis (Annual Result Update)

Aug 5, 2020 | Updated on Aug 5, 2020

Here's an analysis of the annual report of INFOSYS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of INFOSYS. Also includes updates on the valuation of INFOSYS.

Happiest Minds Q4 Results: Profit Grows Over Six-Fold; Company Eyes 20% Organic Growth in FY22 (Views On News)

May 14, 2021

Key takeaways from Happiest Minds Technologies Q4FY21 results.

L&T Technology Shares Fall After Q4 Results. What Should Investors Do? (Views On News)

May 5, 2021

Despite strong deal wins and a low base in FY21, a big turn-off for investors was the muted FY22 revenue growth guidance.

More Views on News

Most Popular

Is Intraday Trading For You? (Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution (Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE IT


May 14, 2021 (Close)

S&P BSE IT 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS